Nuestro blog Melanoma360

Blog - Melanoma360

Featured image for “Transformation after Trauma”
03/14/2023

Transformation after Trauma

Our lives are filled with ups and downs, triumphs and tragedies, success and stress. The question is not whether we…
Blog - Melanoma360
Podcast
Featured image for “U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma”
02/28/2023

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)–  The applications are based on results from the Phase 3 CheckMate -76K trial,…
Blog - Melanoma360
Noticias de última hora
Investigación sobre el melanoma
Featured image for “Functional Nutrition for Cancer Survivors”
02/07/2023

Functional Nutrition for Cancer Survivors

In this episode, we welcome Dione Detraz, RD, integrative dietitian nutritionist and author of The Cancer Diet Cookbook: Comforting Recipes…
Blog - Melanoma360
Podcast
Featured image for “Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?”
01/27/2023

Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?

By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
Blog - Melanoma360
Investigación sobre el melanoma
Featured image for “A Letter From Our Vice President | January 2023”
01/26/2023

A Letter From Our Vice President | January 2023

  Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
Blog - Melanoma360
Investigación sobre el melanoma
Featured image for “TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium”
01/26/2023

TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium

This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
Blog - Melanoma360
Investigación sobre el melanoma
Featured image for “What Makes AIM’s IMTBC Even More Valuable”
01/26/2023

What Makes AIM’s IMTBC Even More Valuable

AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
Blog - Melanoma360
Investigación sobre el melanoma
Featured image for “The Grieving Brain: The Science of Love and Loss”
01/11/2023

The Grieving Brain: The Science of Love and Loss

Our guest Dr. Mary-Frances O’Connor is a renowned grief expert, author, neuroscientist, and an associate professor of psychology at the…
Blog - Melanoma360
Podcast
Featured image for “AIM at Melanoma Earns a Four-Star Rating From Charity Navigator”
12/23/2022

AIM at Melanoma Earns a Four-Star Rating From Charity Navigator

December 21, 2022 (Richmond, California) AIM at Melanoma is proud to announce that its strong financial health and ongoing accountability…
Blog - Melanoma360
Filantropía
Featured image for “The Future of Melanoma Treatment: 2023 and Beyond”
12/19/2022

The Future of Melanoma Treatment: 2023 and Beyond

Melissa Wilson, PA-C, MPAS from UPMC Hillman Cancer Center, and Vernon Sondak, MD, Chair, Department of Cutaneous Oncology, Moffitt Cancer…
Blog - Melanoma360
Podcast
03/14/2023

Transformation after Trauma

Our lives are filled with ups and downs, triumphs and tragedies, success and stress. The question is not whether we…
Featured image for “Transformation after Trauma”
Blog - Melanoma360
 | 
Podcast
02/28/2023

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)–  The applications are based on results from the Phase 3 CheckMate -76K trial,…
Featured image for “U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma”
Blog - Melanoma360
 | 
Noticias de última hora
 | 
Investigación sobre el melanoma
02/07/2023

Functional Nutrition for Cancer Survivors

In this episode, we welcome Dione Detraz, RD, integrative dietitian nutritionist and author of The Cancer Diet Cookbook: Comforting Recipes…
Featured image for “Functional Nutrition for Cancer Survivors”
Blog - Melanoma360
 | 
Podcast
01/27/2023

Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?

By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
Featured image for “Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?”
Blog - Melanoma360
 | 
Investigación sobre el melanoma
01/26/2023

A Letter From Our Vice President | January 2023

  Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
Featured image for “A Letter From Our Vice President | January 2023”
Blog - Melanoma360
 | 
Investigación sobre el melanoma
01/26/2023

TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium

This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
Featured image for “TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium”
Blog - Melanoma360
 | 
Investigación sobre el melanoma
01/26/2023

What Makes AIM’s IMTBC Even More Valuable

AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
Featured image for “What Makes AIM’s IMTBC Even More Valuable”
Blog - Melanoma360
 | 
Investigación sobre el melanoma
01/11/2023

The Grieving Brain: The Science of Love and Loss

Our guest Dr. Mary-Frances O’Connor is a renowned grief expert, author, neuroscientist, and an associate professor of psychology at the…
Featured image for “The Grieving Brain: The Science of Love and Loss”
Blog - Melanoma360
 | 
Podcast
12/23/2022

AIM at Melanoma Earns a Four-Star Rating From Charity Navigator

December 21, 2022 (Richmond, California) AIM at Melanoma is proud to announce that its strong financial health and ongoing accountability…
Featured image for “AIM at Melanoma Earns a Four-Star Rating From Charity Navigator”
Blog - Melanoma360
 | 
Filantropía
12/19/2022

The Future of Melanoma Treatment: 2023 and Beyond

Melissa Wilson, PA-C, MPAS from UPMC Hillman Cancer Center, and Vernon Sondak, MD, Chair, Department of Cutaneous Oncology, Moffitt Cancer…
Featured image for “The Future of Melanoma Treatment: 2023 and Beyond”
Blog - Melanoma360
 | 
Podcast